Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

June 23, 2023

Study Completion Date

July 1, 2026

Conditions
Grade 3b Follicular LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRecurrent Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRefractory Classic Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed Non-Hodgkin Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Vorinostat

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER